Your browser doesn't support javascript.
loading
Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.
Sprini, Delia; Di Stefano, Laura; Rini, Giovam Battista; Cianferotti, Luisella; Napoli, Nicola.
Affiliation
  • Sprini D; Department of Internal Medicine, University of Palermo, Italy.
  • Di Stefano L; Department of Internal Medicine, University of Palermo, Italy.
  • Rini GB; Department of Internal Medicine, University of Palermo, Italy.
  • Cianferotti L; Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
  • Napoli N; Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis MO, USA.
Clin Cases Miner Bone Metab ; 11(2): 126-8, 2014 May.
Article in En | MEDLINE | ID: mdl-25285142
ABSTRACT
Treatment with bisphosphonates induces differentiation and activation of Vγ9Vδ2 T lymphocytes obtained from peripheral blood showing also an antitumoral effect in both in vitro and in vivo models. Aim of the present study was to determine in vivo the effect of BPs treatment in patients affected with osteoporosis on Vγ9Vδ2 T lymphocytes. We have studied Vγ9Vδ2 T lymphocytes expansion and differentiation from PBMC obtained from osteoporotic patients treated with one of the following bisphosphonates zoledronate, alendronate, neridronate or risedronate. We have found that zoledronic acid, followed by alendronate was the most effective on reducing CM population (100%) and increasing TEM and TEMRA γδ population. Our results indicate that in vivo treatment with BPs induces Vγ9Vδ2 cells to mature toward the effector phenotype, which may induce more antiresorptive responses.
Key words

Full text: 1 Database: MEDLINE Language: En Journal: Clin Cases Miner Bone Metab Year: 2014 Type: Article Affiliation country: Italy

Full text: 1 Database: MEDLINE Language: En Journal: Clin Cases Miner Bone Metab Year: 2014 Type: Article Affiliation country: Italy